Pellucid marginal degeneration (PMD) is an eye condition that has been around for a long time, but is still relatively unknown and poorly understood. PMD is a progressive, non-inflammatory condition that causes thinning of the cornea at the outer edge, or margin, of the eye. This can lead to decreased vision, light sensitivity, and other vision-related problems. The exact cause of PMD is unknown, but it is thought to be related to genetics, environmental factors, or a combination of both. In this article, we will explore the mysteries of PMD, discuss the symptoms, diagnosis, and treatment options, and provide an overview of the current research.
Pellucid marginal degeneration (PMD) is a progressive, non-inflammatory eye disease that affects the peripheral cornea. It is characterized by thinning of the cornea at the outer edge, or margin, of the eye. This thinning can cause decreased vision, light sensitivity, and other vision-related problems. PMD is most commonly seen in people between the ages of 20 and 40, although it can occur at any age.
The most common symptom of PMD is decreased vision in the affected eye. This can range from mild to severe, depending on the severity of the condition. Other symptoms may include light sensitivity, glare, halos around lights, double vision, and astigmatism. In some cases, the condition may also cause pain or discomfort.
PMD is typically diagnosed during a comprehensive eye exam. During the exam, the doctor will look for signs of thinning of the cornea at the outer edge of the eye. They may also use a slit lamp to examine the cornea more closely. Imaging tests, such as OCT (optical coherence tomography) or ultrasound, may also be used to confirm the diagnosis.
Treatment of PMD is aimed at relieving symptoms and preserving vision. In most cases, this can be done with glasses, contact lenses, or surgery. In severe cases, corneal transplantation may be necessary.
Currently, there is limited research on PMD, and the exact cause of the condition is unknown. However, researchers believe that genetics, environmental factors, or a combination of both may play a role. Studies have also suggested that PMD may be associated with certain autoimmune diseases, such as rheumatoid arthritis.
Pellucid marginal degeneration is a progressive, non-inflammatory eye condition that can cause decreased vision, light sensitivity, and other vision-related problems. Although the exact cause of PMD is unknown, it is thought to be related to genetics, environmental factors, or a combination of both. Treatment of PMD is aimed at relieving symptoms and preserving vision, and can include glasses, contact lenses, or surgery. Research on PMD is ongoing, and further studies are needed to better understand the condition and develop more effective treatments.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation